



## VistaGen Therapeutics to Present at 11th Annual Biotech Showcase

December 27, 2018

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that it will present at the 11<sup>th</sup> Annual Biotech Showcase, to be held January 7-9, 2019 at the Hilton San Francisco Union Square in San Francisco, California. The Company's presentation will be on Monday, January 7<sup>th</sup> at 2:30 p.m. PST.

[Shawn Singh, Chief Executive Officer of VistaGen](#), will provide an overview of the Company's three clinical-stage CNS product development programs during the live presentation and will be available to participate in one-on-one meetings with attendees who are registered to attend the conference.

Additionally, members of VistaGen's management team will be participating in investor and partnering meetings surrounding the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference to be held January 7-10, 2019 in San Francisco. To request a meeting with management, please contact KCSA Strategic Communications at [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com) to request a meeting.

### About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. Each of VistaGen's CNS pipeline candidates, AV-101, PH10 and PH94B, has potential to provide rapid-onset therapeutic benefits without the psychological side effects, safety concerns or inconvenient clinical administration associated with many current and potential new generation medications for CNS diseases and disorders such as major depressive disorder (MDD), neuropathic pain and social anxiety disorder (SAD). Each drug candidate in VistaGen's pipeline is either currently in or has completed Phase 2 clinical development in the United States. AV-101, an oral NMDA receptor glycine B antagonist, is in Phase 2 development as an adjunctive treatment of MDD. The FDA has granted Fast Track designation for development of AV-101 as both a potential [adjunctive treatment of MDD](#) and as a [non-opioid treatment for neuropathic pain](#). PH10 intranasal, a first-in-class neuroactive steroid with rapid onset effects, is in Phase 2 development for MDD. PH94B intranasal, also a first-in-class neuroactive steroid with rapid onset effects, has completed Phase 2 development and is now being prepared for pivotal Phase 3 clinical development as an on demand (PRN) treatment of SAD.

For more information, please visit [www.vistagen.com](http://www.vistagen.com) and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### Company Contact

Mark A. McPartland  
VistaGen Therapeutics Inc.  
Phone: +1 (650) 577-3600  
Email: [IR@vistagen.com](mailto:IR@vistagen.com)

### Investor Contact

Valter Pinto / Allison Soss  
KCSA Strategic Communications  
Phone: +1 (212) 896-1254/+1 (212) 896-1267  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

### Media Contact

Caitlin Kasunich / Lisa Lipson  
KCSA Strategic Communications  
Phone: +1 (212) 896-1241/+1 (508) 843-6428  
Email: [VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)



VistaGen®  
Therapeutics

Source: VistaGen Therapeutics, Inc.

Released December 27, 2018